Scholarlink

Purpose <p>This study presents a novel strategy to enhance Olaparib delivery for ovarian cancer using statistically optimized silica nanocarriers. It provides enhanced drug loading capacity, moderate cytotoxicity, and controlled release compared to conventional nanoparticles. These advantages help reduce systemic toxicity and increase therapeutic accessibility in BRCA-mutated tumors.</p> Methods <p>Silica nanocarriers were synthesized using the Sol-Gel method and optimized via Box-Behnken Experimental Design, focusing on template concentration, silica precursor, and catalyst volume. Their impact on particle size, drug loading, and zeta potential was systematically assessed. Advanced characterization techniques (FTIR, XRD, TEM, SEM, DLS) confirmed structural and functional attributes, while ovarian cancer cell line studies validated cytotoxicity and therapeutic potential.</p> Results <p>Olaparib-loaded silica nanocarriers were successfully optimized using Box-Behnken Experimental Design, resulting in high drug loading (44.34 ± 0.4%), nanoscale particle size (98.6 ± 0.09&#xa0;nm), and a stable negative zeta potential (-23.11 ± 0.2 mV). Advanced characterization confirmed effective encapsulation and a transition of Olaparib from crystalline to amorphous form, enhancing its solubility. The formulation exhibited sustained, diffusion-controlled drug release, achieving 63.9 ± 0.02% over 12&#xa0;h. It also showed selective cytotoxicity against ovarian cancer cells with minimal effects on normal cells, underscoring its promise for cancer-specific cytotoxic applications.</p> Conclusion <p>This study developed a novel Olaparib-loaded silica nanocarrier system using statistical optimization. The formulation showed high drug loading, sustained diffusion-controlled release, and enhanced solubility through crystalline-to-amorphous transformation. It demonstrated selective cytotoxicity against ovarian cancer cells with minimal toxicity to normal cells, highlighting its potential for ovarian cancer therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development and Optimization of Olaparib-Encapsulated Silica Nanocarriers for Enhanced Therapeutic Efficacy in Ovarian Cancer: Cytotoxicity Profiling in HaCaT and SK-OV-3 Cell Models

  • 期刊论文

  • 发表日期：

    2026年1月6日

查看全文
  • Ankita Gupta,
  • Swatantra Kumar Singh Kushwaha,
  • Amit Mishra

摘要

Purpose

This study presents a novel strategy to enhance Olaparib delivery for ovarian cancer using statistically optimized silica nanocarriers. It provides enhanced drug loading capacity, moderate cytotoxicity, and controlled release compared to conventional nanoparticles. These advantages help reduce systemic toxicity and increase therapeutic accessibility in BRCA-mutated tumors.

Methods

Silica nanocarriers were synthesized using the Sol-Gel method and optimized via Box-Behnken Experimental Design, focusing on template concentration, silica precursor, and catalyst volume. Their impact on particle size, drug loading, and zeta potential was systematically assessed. Advanced characterization techniques (FTIR, XRD, TEM, SEM, DLS) confirmed structural and functional attributes, while ovarian cancer cell line studies validated cytotoxicity and therapeutic potential.

Results

Olaparib-loaded silica nanocarriers were successfully optimized using Box-Behnken Experimental Design, resulting in high drug loading (44.34 ± 0.4%), nanoscale particle size (98.6 ± 0.09 nm), and a stable negative zeta potential (-23.11 ± 0.2 mV). Advanced characterization confirmed effective encapsulation and a transition of Olaparib from crystalline to amorphous form, enhancing its solubility. The formulation exhibited sustained, diffusion-controlled drug release, achieving 63.9 ± 0.02% over 12 h. It also showed selective cytotoxicity against ovarian cancer cells with minimal effects on normal cells, underscoring its promise for cancer-specific cytotoxic applications.

Conclusion

This study developed a novel Olaparib-loaded silica nanocarrier system using statistical optimization. The formulation showed high drug loading, sustained diffusion-controlled release, and enhanced solubility through crystalline-to-amorphous transformation. It demonstrated selective cytotoxicity against ovarian cancer cells with minimal toxicity to normal cells, highlighting its potential for ovarian cancer therapy.